Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Patients with primary advanced inoperable disease who were refractory to chemotherapy

• Patients with recurrent disease following post-operative adjuvant chemotherapy

• Patients who were not amenable to post-recurrence chemotherapy

Exclusion Criteria:

• Patients with serious, uncontrolled medical illness

• Patients with previous therapy with taxanes